{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-175284","form_type":"8-K","ticker":"RNTX","cik":"0001420565","company_name":"Rein Therapeutics, Inc.","filed_at":"2022-06-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.618548+00:00","generated_at":"2026-06-25T01:12:22.396589+00:00","sec_items":["5.02","5.07"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aileron appoints interim CFO; shareholders approve reverse stock split (1:5–1:25)","bullets":["Susan L. Drexler appointed interim CFO effective June 16, 2022, via consulting agreement with Danforth Advisors.","Shareholders approved reverse stock split (1:5 to 1:25) and proportional increase in authorized shares, board to set ratio by Dec 31, 2022.","Stockholders ratified PwC as independent auditor for fiscal year 2022.","William McKee and Nolan Sigal re-elected as Class II directors for three-year terms."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-175284","json":"https://secwatch.observer/filing/0001193125-22-175284.json","markdown":"https://secwatch.observer/filing/0001193125-22-175284.md","text":"https://secwatch.observer/filing/0001193125-22-175284.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420565/000119312522175284/0001193125-22-175284-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420565/000119312522175284/d256872d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T01:12:22.396589+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dd153ecab3","claim":"Susan L. Drexler was appointed as interim chief financial officer at Rein Therapeutics, Inc..","evidence_excerpt":"On June 15, 2022, the Board of Directors of Aileron Therapeutics, Inc. (the “Company”) appointed Susan L. Drexler, a consultant at Danforth Advisors, LLC (“Danforth”), as interim chief financial officer, effective as of June 16, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312522175284/0001193125-22-175284-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim chief financial officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}